Compare ACADIA Pharmaceuticals Inc. (ACAD) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs NextEra Energy, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while NextEra Energy, Inc. trades at $85.81 (market cap $176.68B). The key difference: NextEra Energy, Inc. is far larger — about 34.9× ACADIA Pharmaceuticals Inc.'s market cap, and NextEra Energy, Inc. pays a 2.94% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NEE | |
|---|---|---|
Market Cap | $5.06B | $176.68B |
Sector | Health | Utilities |
52-Week High | $29.39 | $97.88 |
52-Week Low | $20.06 | $69.77 |
Enterprise Value | $4.18B | $284.01B |
Dividend Yield | — | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
NextEra Energy (NEE) trades at $84.65, showing minimal daily movement with a 0.06% gain. The stock is in a bearish technical phase, with support at $84 and resistance at $86. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 missed. The company benefits from strong AI-driven power demand, highlighted by a $100 billion data center project in Kentucky announced on July 29, 2026 (Reuters).
NEE offers solid fundamentals with a 32.4% net income margin and 17.23% ROE, but faces risks from high debt levels and capital expenditures. Analysts are bullish with a $101.17 consensus price target, implying 19% upside. Key opportunities include AI infrastructure growth, while risks involve execution on large projects and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
